Paris, France — September 25th, 2025 — Plantibodies, a French biotech company pioneering oral delivery of biologics through plant-based bioencapsulation, today announced a sponsored research agreement with a Nasdaq-listed biopharmaceutical company pursuing rare gastrointestinal disease.
The collaboration will assess the feasibility of using Plantibodies’ proprietary platform to produce and deliver a therapeutic candidate directly to the colon via oral administration — a breakthrough route for large biologics such as monoclonal antibodies, peptides, or enzymes.
“This agreement is a validation of our platform’s potential to solve major delivery challenges,” said Pierre Bauër, CEO of Plantibodies. “Oral biologics remain a largely untapped frontier — we are proud to work with leading partners to transform patient outcomes.”
The multi-phase program includes in vitro production as well as preclinical biodistribution, safety, and early efficacy preclinical studies.
About Plantibodies
Plantibodies is a biotech company developing a scalable platform for oral delivery of biologics using plant cells for both expression and bioencapsulation. The platform enables targeted delivery to the colon, opening new possibilities in IBD, colorectal cancer, infectious and rare diseases. Learn more at www.plantibodies.tech.
Contact:
Pierre Bauër
CEO, Plantibodies
pierre.bauer@plantibodies.tech